+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Point-of-Care Molecular Diagnostics Market Size, Share & Trends Analysis Report by Application (Infectious Disease, Oncology), Test Location, Technology (PCR Based, Genetic Sequencing Based), End Use, Country with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • February 2025
  • Region: Europe
  • Grand View Research
  • ID: 6056050
Description Jump to:
The Europe Point-of-Care Molecular Diagnostics Market was valued at USD 1.43 billion in 2024, and is projected to reach USD 2.17 billion by 2030, rising at a CAGR of 7.50%. The market growth is primarily driven by the rising prevalence of infectious diseases & chronic disorders, and the growing demand for rapid test results to ensure enhanced patient outcomes.

In recent years, Europe has experienced multiple outbreaks of infectious diseases, such as vector-borne diseases like West Nile virus (WNV) and dengue fever. This has developed a demand for effective technologies, such as point-of-care molecular diagnostics, to ensure seamless operations in burdened healthcare facilities and clinics. Utilization of point-of-care molecular diagnostics has provided benefits such as quick test results, improved accuracy, reduced costs, and enhanced management of operations in the healthcare sector.

Innovation, inclusion of modern technologies, and availability through over-the-counter product ranges have driven the growth of this market. Utilization of in-home care for patients, a wide range of technology capabilities, and ease of accessibility are expected to drive the market growth during the forecast period. The use of PoC molecular diagnostics in identifying specific mutations during cancer tests is projected to add growth opportunities.

Europe Point-of-Care Molecular Diagnostics Market Report Highlights

  • Based on application, infectious diseases dominated with more than 60.0% revenue share in 2024. This is owing to the growing prevalence of communicable diseases in Europe, novel PoC solutions, and increasing use by healthcare professionals for rapid results.
  • The oncology segment is expected to grow at the fastest CAGR in the European point-of-care molecular diagnostics market over the forecast period.
  • Based on test location, the POC technology segment held the largest revenue share of 93.4%, in 2024. The OTC segment is expected to witness the fastest CAGR during the forecast period.
  • Based on technology, PCR-based point-of-care molecular diagnostics dominated the European market with a revenue share of 67.3% in 2024. A genetic sequencing-based segment is anticipated to witness the fastest CAGR of 8.8% over the forecast period.
  • Increasing research and development spending, the launch of novel solutions by key market participants, and the efficiency offered by PoC testing, especially during infectious disease outbreaks, contribute to the growth of the European point-of-care molecular diagnostics market.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Application
1.2.2. Test Location
1.2.3. Technology
1.2.4. End Use
1.2.5. Country
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Europe Point-Of-Care Molecular Diagnostics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Europe Point-Of-Care Molecular Diagnostics Market: Application Estimates & Trend Analysis
4.1. Application Market Share, 2024 & 2030
4.2. Application Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
4.4. Infectious Diseases
4.4.1. Infectious Diseases Market, 2018-2030 (USD Million)
4.4.2. HIV POC
4.4.2.1. HIV POC Market, 2018-2030 (USD Million)
4.4.3. Clostridium Difficile POC
4.4.3.1. Clostridium Difficile POC Market, 2018-2030 (USD Million)
4.4.4. HBV POC
4.4.4.1. HBV POC Market, 2018-2030 (USD Million)
4.4.5. Pneumonia Or Streptococcus Associated Infections
4.4.5.1. Pneumonia Or Streptococcus Associated Infections Market, 2018-2030 (USD Million)
4.4.6. Respiratory Syncytial Virus (RSV) POC
4.4.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2018-2030 (USD Million)
4.4.7. HPV POC
4.4.7.1. HPV POC Market, 2018-2030 (USD Million)
4.4.8. Influenza/Flu POC
4.4.8.1. Influenza/Flu POC Market, 2018-2030 (USD Million)
4.4.9. HCV POC
4.4.9.1. HCV POC Market, 2018-2030 (USD Million)
4.4.10. MRSA POC
4.4.10.1. MRSA POC Market, 2018-2030 (USD Million)
4.4.11. TB And Drug-Resistant TB POC
4.4.11.1. TB And Drug-Resistant TB POC Market, 2018-2030 (USD Million)
4.4.12. HSV POC
4.4.12.1. HSV POC Market, 2018-2030 (USD Million)
4.4.13. Other Infectious Diseases
4.4.13.1. Other Infectious Diseases Market, 2018-2030 (USD Million)
4.5. Oncology
4.5.1. Oncology Market, 2018-2030 (USD Million)
4.6. Hematology
4.6.1. Oncology Market, 2018-2030 (USD Million)
4.6.2. Complete Blood Count (CBC)
4.6.2.1. Complete Blood Count (CBC) Market, 2018-2030 (USD Million)
4.6.3. Prothrombin Time (PT)
4.6.3.1. Complete Blood Count (CBC) Market, 2018-2030 (USD Million)
4.6.4. Partial Thromboplastin Time (PTT)
4.6.4.1. Partial Thromboplastin Time (PTT) Market, 2018-2030 (USD Million)
4.6.5. Others
4.6.5.1. Others Market, 2018-2030 (USD Million)
4.6.6. Prenatal Testing
4.6.6.1. Prenatal Testing Market, 2018-2030 (USD Million)
4.6.7. Endocrinology
4.6.7.1. Endocrinology Market, 2018-2030 (USD Million)
4.6.8. Other Applications
4.6.8.1. Other Applications Market, 2018-2030 (USD Million)
Chapter 5. Europe Point-Of-Care Molecular Diagnostics Market: Test Location Estimates & Trend Analysis
5.1. Test Location Market Share, 2024 & 2030
5.2. Test Location Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Test Location, 2018 to 2030 (USD Million)
5.4. OTC
5.4.1. OTC Market, 2018-2030 (USD Million)
5.5. POC
5.5.1. POC Market, 2018-2030 (USD Million)
Chapter 6. Europe Point-Of-Care Molecular Diagnostics Market: Technology Estimates & Trend Analysis
6.1. Technology Market Share, 2024 & 2030
6.2. Technology Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Technology, 2018 to 2030 (USD Million)
6.4. PCR-based
6.4.1. PCR-based Market, 2018-2030 (USD Million)
6.5. Genetic Sequencing-based
6.5.1. Genetic Sequencing-based Market, 2018-2030 (USD Million)
6.6. Hybridization-based
6.6.1. Hybridization-based Market, 2018-2030 (USD Million)
6.7. Microarray-based
6.7.1. Microarray-based Market, 2018-2030 (USD Million)
Chapter 7. Europe point-of-care molecular diagnostics Market: End Use Estimates & Trend Analysis
7.1. End Use Channel Market Share, 2024 & 2030
7.2. End Use Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
7.4. Decentralized Labs
7.4.1. Decentralized Labs Market, 2018-2030 (USD Million)
7.5. Hospitals
7.5.1. Hospitals Market, 2018-2030 (USD Million)
7.6. Home-care
7.6.1. Home-care Market, 2018-2030 (USD Million)
7.7. Assisted Living Healthcare Facilities
7.7.1. Assisted Living Healthcare Facilities Market, 2018-2030 (USD Million)
7.8. Other Uses
7.8.1. Other Uses Market, 2018-2030 (USD Million)
Chapter 8. Medical Carts Market: Country Estimates & Trend Analysis
8.1. Country Market Share Analysis, 2024 & 2030
8.2. Country Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3.1. UK
8.3.1.1. Key Country Dynamics
8.3.1.2. Regulatory Framework
8.3.1.3. Competitive Insights
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Regulatory Framework
8.3.2.3. Competitive Insights
8.3.3. France
8.3.3.1. Key Country Dynamics
8.3.3.2. Regulatory Framework
8.3.3.3. Competitive Insights
8.3.4. Italy
8.3.4.1. Key Country Dynamics
8.3.4.2. Regulatory Framework
8.3.4.3. Competitive Insights
8.3.5. Spain
8.3.5.1. Key Country Dynamics
8.3.5.2. Regulatory Framework
8.3.5.3. Competitive Insights
8.3.6. Denmark
8.3.6.1. Key Country Dynamics
8.3.6.2. Regulatory Framework
8.3.6.3. Competitive Insights
8.3.7. Sweden
8.3.7.1. Key Country Dynamics
8.3.7.2. Regulatory Framework
8.3.7.3. Competitive Insights
8.3.8. Norway
8.3.8.1. Key Country Dynamics
8.3.8.2. Regulatory Framework
8.3.8.3. Competitive Insights
8.3.9. Russia
8.3.9.1. Key Country Dynamics
8.3.9.2. Regulatory Framework
8.3.9.3. Competitive Insights
8.3.10. Netherlands
8.3.10.1. Key Country Dynamics
8.3.10.2. Regulatory Framework
8.3.10.3. Competitive Insights
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Abbott
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. QIAGEN
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Bayer AG
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Nova Biomedical
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Danaher
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Nipro Diagnostics (Nipro Europe Group Companies)
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Bio-Rad Laboratories, Inc.
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Agilent Technologies, Inc.
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. BIOMÉRIEUX
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. OraSure Technologies Inc.
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
9.5.11. Abaxis
9.5.11.1. Overview
9.5.11.2. Financial Performance
9.5.11.3. Product Benchmarking
9.5.11.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Europe point-of-care molecular diagnostics market, by country, 2018-2030 (USD Million)
Table 4. Europe point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 5. Europe point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 6. Europe point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 7. Europe point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
Table 8. UK point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 9. UK point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 10. UK point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 11. UK point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
Table 12. Germany point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 13. Germany point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 14. Germany point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 15. Germany point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
Table 16. France point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 17. France point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 18. France point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 19. France point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
Table 20. Italy point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 21. Italy point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 22. Italy point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 23. Italy point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
Table 24. Spain point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 25. Spain point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 26. Spain point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 27. Spain point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
Table 28. Denmark point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 29. Denmark point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 30. Denmark point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 31. Denmark point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
Table 32. Sweden point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 33. Sweden point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 34. Sweden point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 35. Sweden point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
Table 36. Norway point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 37. Norway point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 38. Norway point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 39. Norway point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
Table 40. Russia point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 41. Russia point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 42. Russia point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 43. Russia point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
Table 44. Netherlands point-of-care molecular diagnostics market, by application, 2018-2030 (USD Million)
Table 45. Netherlands point-of-care molecular diagnostics market, by test location, 2018-2030 (USD Million)
Table 46. Netherlands point-of-care molecular diagnostics market, by technology, 2018-2030 (USD Million)
Table 47. Netherlands point-of-care molecular diagnostics market, by end use, 2018-2030 (USD Million)
List of Figures
Figure 1 Europe point-of-care molecular diagnostics market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Application and test location outlook (USD Million)
Figure 10 Technology and end use outlook (USD Million)
Figure 11 Competitive landscape
Figure 12 Europe point-of-care molecular diagnostics market dynamics
Figure 13 Europe point-of-care molecular diagnostics market: Porter’s five forces analysis
Figure 14 Europe point-of-care molecular diagnostics market: PESTLE analysis
Figure 15 Europe point-of-care molecular diagnostics market: Application segment dashboard
Figure 16 Europe point-of-care molecular diagnostics market: Application market share analysis, 2024 & 2030
Figure 17 Infectious diseases market, 2018-2030 (USD Million)
Figure 18 HIV POC market, 2018-2030 (USD Million)
Figure 19 Clostridium difficile POC market, 2018-2030 (USD Million)
Figure 20 HBV POC market, 2018-2030 (USD Million)
Figure 21 Pneumonia or streptococcus associated infections market, 2018-2030 (USD Million)
Figure 22 Respiratory Syncytial Virus (RSV) POC market, 2018-2030 (USD Million)
Figure 23 HPV POC market, 2018-2030 (USD Million)
Figure 24 Influenza/Flu POC market, 2018-2030 (USD Million)
Figure 25 HCV POC market, 2018-2030 (USD Million)
Figure 26 MRSA POC market, 2018-2030 (USD Million)
Figure 27 TB and drug-resistant TB POC market, 2018-2030 (USD Million)
Figure 28 HSV POC market, 2018-2030 (USD Million)
Figure 29 Other infectious diseases market, 2018-2030 (USD Million)
Figure 30 Oncology market, 2018-2030 (USD Million)
Figure 31 Hematology market, 2018-2030 (USD Million)
Figure 32 Prenatal testing market, 2018-2030 (USD Million)
Figure 33 Endocrinology market, 2018-2030 (USD Million)
Figure 34 Other applications market, 2018-2030 (USD Million)
Figure 35 Europe point-of-care molecular diagnostics market: Test location segment dashboard
Figure 36 Europe point-of-care molecular diagnostics market: Test location market share analysis, 2024 & 2030
Figure 37 OTC market, 2018-2030 (USD Million)
Figure 38 POC market, 2018-2030 (USD Million)
Figure 39 Europe point-of-care molecular diagnostics market : Technology segment dashboard
Figure 40 Europe point-of-care molecular diagnostics market: Technology market share analysis, 2024 & 2030
Figure 41 PCR-based market, 2018-2030 (USD Million)
Figure 42 Genetic Sequencing-based market, 2018-2030 (USD Million)
Figure 43 Hybridization-based market, 2018-2030 (USD Million)
Figure 44 Microarray-based market, 2018-2030 (USD Million)
Figure 45 Europe point-of-care molecular diagnostics market : End use segment dashboard
Figure 46 Europe point-of-care molecular diagnostics market: End use market share analysis, 2024 & 2030
Figure 47 Decentralized labs market, 2018-2030 (USD Million)
Figure 48 Hospitals market, 2018-2030 (USD Million)
Figure 49 Home-care market, 2018-2030 (USD Million)
Figure 50 Assisted living healthcare facilities market, 2018-2030 (USD Million)
Figure 51 Other uses market, 2018-2030 (USD Million)
Figure 52 Europe point-of-care molecular diagnostics market : Country segment dashboard
Figure 53 Europe point-of-care molecular diagnostics market: Country channel market share analysis, 2024 & 2030
Figure 54 Hospital pharmacies market, 2018-2030 (USD Million)
Figure 55 Retail pharmacies market, 2018-2030 (USD Million)
Figure 56 Others market, 2018-2030 (USD Million)
Figure 57 Europe point-of-care molecular diagnostics market : Country segment dashboard
Figure 58 Europe point-of-care molecular diagnostics market: Country market share analysis, 2024 & 2030
Figure 59 UK
Figure 60 UK market, 2018-2030 (USD Million)
Figure 61 Germany
Figure 62 Germany market, 2018-2030 (USD Million)
Figure 63 France
Figure 64 France market, 2018-2030 (USD Million)
Figure 65 Italy
Figure 66 Italy market, 2018-2030 (USD Million)
Figure 67 Spain
Figure 68 Spain market, 2018-2030 (USD Million)
Figure 69 Denmark
Figure 70 Denmark market, 2018-2030 (USD Million)
Figure 71 Sweden
Figure 72 Sweden market, 2018-2030 (USD Million)
Figure 73 Norway
Figure 74 Norway market, 2018-2030 (USD Million)
Figure 75 Russia
Figure 76 Russia market, 2018-2030 (USD Million)
Figure 77 Netherlands
Figure 78 Netherlands market, 2018-2030 (USD Million)
Figure 79 Company categorization
Figure 80 Company market position analysis
Figure 81 Strategic framework

Companies Mentioned

The major companies profiled in this Europe Point-of-Care Molecular Diagnostics market report include:
  • Abbott
  • QIAGEN
  • Bayer AG
  • Nova Biomedical
  • Danaher
  • Nipro Diagnostics (Nipro Europe Group Companies)
  • Bio-Rad Laboratories, Inc
  • Agilent Technologies, Inc.
  • BIOMÉRIEUX
  • OraSure Technologies Inc.
  • Abaxis

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.43 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.17 Billion
Compound Annual Growth Rate7.5%
Regions CoveredEurope
No. of Companies Mentioned11

Related Topics

Related Reports

Point-of-Care Molecular Diagnostics Market Size, Share & Trends Analysis Report by Application (Infectious Diseases, Oncology, Prenatal Testing), Technology, Test Location, End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Point-of-Care Molecular Diagnostics Market Size, Share & Trends Analysis Report by Application (Infectious Diseases, Oncology, Prenatal Testing), Technology, Test Location, End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 150 Pages
  • Global
From
In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030 - Product Image

In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030

  • Report
  • 526 Pages
  • Global
From
Point of Care Molecular Diagnostics Market by Product, Technology, Application, End-User - Global Forecast 2025-2030 - Product Image

Point of Care Molecular Diagnostics Market by Product, Technology, Application, End-User - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
North America Point Of Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Infectious Diseases, Glucose Testing, Cardiac Markers), By Type, By End-use (Clinics, Home Care, Hospitals), By Country, And Segment Forecasts, 2023 - 2030 - Product Image

North America Point Of Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Infectious Diseases, Glucose Testing, Cardiac Markers), By Type, By End-use (Clinics, Home Care, Hospitals), By Country, And Segment Forecasts, 2023 - 2030

  • Report
  • 180 Pages
  • North America
From
Point-of-Care Diagnostics Market by Platform (LFA, Molecular), Application (TB, Pneumonia, Salmonellosis, Hepatitis, HIV, COVID-19, Pregnancy, Blood Glucose Monitoring, Hematology, Tumor), Sample Type (Blood, Urine), and End User - Global Forecast to 2030 - Product Image

Point-of-Care Diagnostics Market by Platform (LFA, Molecular), Application (TB, Pneumonia, Salmonellosis, Hepatitis, HIV, COVID-19, Pregnancy, Blood Glucose Monitoring, Hematology, Tumor), Sample Type (Blood, Urine), and End User - Global Forecast to 2030

  • Report
  • 395 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.